Carsten-Oliver Sahlmann1, Birgit Meller2, Caroline Bouter2, Christian Oliver Ritter3, Philipp Ströbel4, Joachim Lotz3, Lutz Trojan5, Johannes Meller2, Sameh Hijazi5. 1. Department of Nuclear Medicine, University Medical Center Goettingen, Robert-Koch-Str. 40, D-37075, Goettingen, Germany. sahlmann@med.uni-goettingen.de. 2. Department of Nuclear Medicine, University Medical Center Goettingen, Robert-Koch-Str. 40, D-37075, Goettingen, Germany. 3. Department of Diagnostic and Interventional Radiology, University Medical Center Goettingen, Goettingen, Germany. 4. Department of Pathology, University Medical Center Goettingen, Goettingen, Germany. 5. Department of Urology, University Medical Center Goettingen, Goettingen, Germany.
Abstract
PURPOSE: Binding of (68)Ga-PSMA-HBED-CC ((68)Ga-PSMA) at prostate cancer (PC) cells increases over time. A biphasic protocol may help separating benign from tumor lesions. The aim of this study was the retrospective evaluation of a diagnostic incremental value of a dual-time point (biphasic) (68)Ga-PSMA-PET/CT in patients with prostate cancer. METHODS: Retrospective analysis of 35 consecutive patients (49-78 years, median 71) with newly diagnosed PC (12/35) or recurrence of PC (23/35). PET/CT (Gemini TF16, Philips) was acquired 1 h and 3 h p. i. of 140-392 MBq (300 MBq median) (68)Ga-PSMA, followed by a diagnostic contrast CT. PET findings were correlated with histology or unequivocal CT findings. Semiquantitative PET data (SUVmax, SUV mean) were acquired and target-to-background-ratios (T/B-ratio) were calculated for benign and malign lesions for both time points. Size of lymph nodes (LN) on diagnostic CT was recorded. Statistical analysis was performed for assessment of significant changes of semiquantitative PET-parameters over time and for correlation of size and uptake of lymph nodes. RESULTS: One hundred and four lesions were evaluated. Sixty lesions were referenced by histology or unequivocal CT findings, including eight (13.3 %) histopathologically benign lymph nodes, 12 (20 %) histopathologically lymph node metastases, 12 (20 %) primary tumors, three (5 %) local recurrences, and 25 (41.7 %) bone metastases. Forty-four lesions were axillary LN with normal CT-appearance. Benign lesions had significantly lower SUVmax and T/B-ratios compared with malignant findings. Malign lesions showed a significant increase of both parameters over time compared to benign findings. There was no correlation between LN size and SUVmax. The sensitivity, specificity, the positive predictive value and negative predictive value of PET/CT regarding pelvic LN was 94 %, 99 %, 89 %, and 99.5 %, respectively. CONCLUSIONS: In contrast to benign tissues, the uptake of proven tumor lesions increases on (68)Ga-PSMA-PET/CT over time. A biphasic PET-study may lead to a better detection of tumor lesions in unequivocal findings.
PURPOSE: Binding of (68)Ga-PSMA-HBED-CC ((68)Ga-PSMA) at prostate cancer (PC) cells increases over time. A biphasic protocol may help separating benign from tumor lesions. The aim of this study was the retrospective evaluation of a diagnostic incremental value of a dual-time point (biphasic) (68)Ga-PSMA-PET/CT in patients with prostate cancer. METHODS: Retrospective analysis of 35 consecutive patients (49-78 years, median 71) with newly diagnosed PC (12/35) or recurrence of PC (23/35). PET/CT (Gemini TF16, Philips) was acquired 1 h and 3 h p. i. of 140-392 MBq (300 MBq median) (68)Ga-PSMA, followed by a diagnostic contrast CT. PET findings were correlated with histology or unequivocal CT findings. Semiquantitative PET data (SUVmax, SUV mean) were acquired and target-to-background-ratios (T/B-ratio) were calculated for benign and malign lesions for both time points. Size of lymph nodes (LN) on diagnostic CT was recorded. Statistical analysis was performed for assessment of significant changes of semiquantitative PET-parameters over time and for correlation of size and uptake of lymph nodes. RESULTS: One hundred and four lesions were evaluated. Sixty lesions were referenced by histology or unequivocal CT findings, including eight (13.3 %) histopathologically benign lymph nodes, 12 (20 %) histopathologically lymph node metastases, 12 (20 %) primary tumors, three (5 %) local recurrences, and 25 (41.7 %) bone metastases. Forty-four lesions were axillary LN with normal CT-appearance. Benign lesions had significantly lower SUVmax and T/B-ratios compared with malignant findings. Malign lesions showed a significant increase of both parameters over time compared to benign findings. There was no correlation between LN size and SUVmax. The sensitivity, specificity, the positive predictive value and negative predictive value of PET/CT regarding pelvic LN was 94 %, 99 %, 89 %, and 99.5 %, respectively. CONCLUSIONS: In contrast to benign tissues, the uptake of proven tumor lesions increases on (68)Ga-PSMA-PET/CT over time. A biphasic PET-study may lead to a better detection of tumor lesions in unequivocal findings.
Authors: S Hijazi; B Meller; C Leitsmann; A Strauss; J Meller; C O Ritter; J Lotz; H-U Schildhaus; L Trojan; C O Sahlmann Journal: Prostate Date: 2015-09-10 Impact factor: 4.104
Authors: Dan J Kadrmas; Michael E Casey; Maurizio Conti; Bjoern W Jakoby; Cristina Lois; David W Townsend Journal: J Nucl Med Date: 2009-07-17 Impact factor: 10.057
Authors: A Afshar-Oromieh; A Malcher; M Eder; M Eisenhut; H G Linhart; B A Hadaschik; T Holland-Letz; F L Giesel; C Kratochwil; S Haufe; U Haberkorn; C M Zechmann Journal: Eur J Nucl Med Mol Imaging Date: 2012-11-24 Impact factor: 9.236
Authors: Sigrid A Rajasekaran; Gopalakrishnapillai Anilkumar; Eri Oshima; James U Bowie; He Liu; Warren Heston; Neil H Bander; Ayyappan K Rajasekaran Journal: Mol Biol Cell Date: 2003-10-03 Impact factor: 4.138
Authors: Markus Dietlein; Carsten Kobe; Georg Kuhnert; Simone Stockter; Thomas Fischer; Klaus Schomäcker; Matthias Schmidt; Felix Dietlein; Boris D Zlatopolskiy; Philipp Krapf; Raphael Richarz; Stephan Neubauer; Alexander Drzezga; Bernd Neumaier Journal: Mol Imaging Biol Date: 2015-08 Impact factor: 3.488
Authors: Thorsten Derlin; Sebastian Schmuck; Cathleen Juhl; Johanna Zörgiebel; Sophie M Schneefeld; Almut C A Walte; Katja Hueper; Christoph A von Klot; Christoph Henkenberens; Hans Christiansen; James T Thackeray; Tobias L Ross; Frank M Bengel Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-07 Impact factor: 9.236
Authors: Sebastian Schmuck; Stefan Nordlohne; Christoph-A von Klot; Christoph Henkenberens; Jan M Sohns; Hans Christiansen; Hans-Jürgen Wester; Tobias L Ross; Frank M Bengel; Thorsten Derlin Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-09 Impact factor: 9.236
Authors: Christian Uprimny; Alexander Stephan Kroiss; Clemens Decristoforo; Josef Fritz; Elisabeth von Guggenberg; Dorota Kendler; Lorenza Scarpa; Gianpaolo di Santo; Llanos Geraldo Roig; Johanna Maffey-Steffan; Wolfgang Horninger; Irene Johanna Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2017-01-31 Impact factor: 9.236
Authors: Ali Afshar-Oromieh; Bernd Vollnberg; Ian Alberts; Alexandrine Bähler; Christos Sachpekidis; Lotte Dijkstra; Fabian Haupt; Silvan Boxler; Tobias Gross; Tim Holland-Letz; George Thalmann; Johannes Heverhagen; Axel Rominger; Kirsi Härmä; Martin H Maurer Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-27 Impact factor: 9.236
Authors: Ali Afshar-Oromieh; Lars Peter Sattler; Katja Steiger; Tim Holland-Letz; Marcelo Livorsi da Cunha; Walter Mier; Oliver Neels; Klaus Kopka; Wilko Weichert; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2018-03-01 Impact factor: 9.236